• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Cephalon

Cephalon

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Why Retirement Funds Fall Short

    Cephalon CEPH announced Monday that Gabitril did not meet the primary endpoints in a Phase III study for generalized anxiety disorder (GAD). We're sticking with our fair value estimate of $44 per share, as we had assumed only a modest increase in Gabitril sales from this additional indication. ...

  2. Compelling Financial Benefit in Valeant's Latest Buy

    The proposed Salix acquisition boosts our fair value estimate significantly.

1
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.